Ferring divests testosterone drug in new deal

In move towards simplifying its urology treatment portfolio, Ferring has divested two drugs, one of which is a topical treatment for adult male hypogonadism.

Photo: Thomas Borberg

Swiss pharmaceutical firm Ferring has divested two urology-related medicines.

Simple Pharma is the buyer, and this firm has previously taken drugs off the hands of major pharmaceutical firms. The sales price has not been fully established, but the drugs are in the markets of 20 and 15 countries, respectively, with more launches in the works.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs